Joins Experienced Team to Accelerate Global Launch of the new Sonata 2 System Redwood City, CA – November 8, 2019 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive
Gynesonics Announces Five-Year Patient Outcomes with the Sonata System Published in Journal of Gynecologic Surgery
VITALITY Study Demonstrates the Long-Term Durability of Patient Outcomes In Treating Symptomatic Uterine Fibroids Redwood City, CA – March 5, 2019 - Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas)
Gynesonics Announces Publication of Final SONATA IDE Pivotal Trial Results in the Journal, Obstetrics And Gynecology
Robust Outcomes Support the Potential of the Sonata System as a First-Line Treatment for Symptomatic Uterine Fibroids Redwood City, CA – January 10, 2019 - Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as
Gynesonics Announces $75 Million Equity Financing
Equity Round led by Bain Capital Life Sciences Redwood City, CA – January 3, 2019 - Gynesonics, a women’s healthcare company and the developer of the Sonata System and other advanced, incision-free solutions for the treatment of uterine conditions, today announced that it has completed a $75
Gynesonics Technology to be Featured in Presentations at 2018 AAGL Global Congress
Impressive 12-Month Patient Outcomes from SONATA Pivotal IDE Trial Being Highlighted Redwood City, CA – Nov 12, 2018 - Gynesonics, a women’s healthcare company focused on the development of advanced minimally invasive solutions for the treatment of uterine conditions, today announced that its
Gynesonics Receives FDA Clearance to Market Sonata® System
Advanced technology offers potential to become a new standard of care for fibroid treatment Redwood City, CA – August 22, 2018 - Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, today announced that it has received
Gynesonics Announces Results from Pivotal IDE Trial for Incision Free Treatment of Uterine Fibroids
Results highlight robust Sonata System design and its potential to become a standard of care for fibroid treatment Redwood City, CA – January 9, 2018 - Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today
Gynesonics Announces Submission of FDA 510K for Incision-Free Treatment of Symptomatic Uterine Fibroids
Novel uterus-preserving Sonata System is first incision-free treatment to address majority of fibroids transcervically Redwood City, CA – December 21, 2017 - Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for uterine fibroids, today announced its